Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study
Abstract Background Immunization with meningococcal ACWY conjugate vaccine induces protective antibodies against invasive meningococcal disease (IMD) caused by serogroups A, C, W and Y. We studied MenACWY-TT vaccine immunogenicity in adolescents with a heterogenous group of primary and secondary imm...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-07-01
|
| Series: | Pediatric Rheumatology Online Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12969-023-00846-3 |
| _version_ | 1797774372175347712 |
|---|---|
| author | Milou Ohm Joeri W van Straalen Gerrie de Joode-Smink Joris van Montfrans Marije Bartels Joanne G van Wildenbeest Caroline A Lindemans Roos AW Wennink Joke H de Boer Elisabeth AM Sanders Frans M Verduyn-Lunel Guy AM Berbers Nico M Wulffraat Marc H.A. Jansen |
| author_facet | Milou Ohm Joeri W van Straalen Gerrie de Joode-Smink Joris van Montfrans Marije Bartels Joanne G van Wildenbeest Caroline A Lindemans Roos AW Wennink Joke H de Boer Elisabeth AM Sanders Frans M Verduyn-Lunel Guy AM Berbers Nico M Wulffraat Marc H.A. Jansen |
| author_sort | Milou Ohm |
| collection | DOAJ |
| description | Abstract Background Immunization with meningococcal ACWY conjugate vaccine induces protective antibodies against invasive meningococcal disease (IMD) caused by serogroups A, C, W and Y. We studied MenACWY-TT vaccine immunogenicity in adolescents with a heterogenous group of primary and secondary immune deficiency including patients with systemic lupus erythematosus, mixed connective tissue disease, vasculitis, uveitis, 22Q11 syndrome, sickle cell disease, and patients who underwent stem cell transplantation for bone marrow failure. Findings We enrolled 69 individuals aged 14–18 years diagnosed with a primary or secondary immune deficiency in a prospective observational cohort study. All patients received a single dose of MenACWY-TT vaccine during the catch-up campaign 2018-19 because of the IMD-W outbreak in the Netherlands. Capsular polysaccharide-specific (PS) IgG concentrations against MenACWY were measured before and 3–6, 12, and 24 months after vaccination. Overall, geometric mean concentrations (GMCs) of MenACWY-PS-specific IgG were lower in patients compared to data from healthy, aged-matched controls (n = 75) reaching significance at 12 months postvaccination for serogroup A and W (adjusted GMC ratios 0.26 [95% CI: 0.15–0.47] and 0.22 [95% CI: 0.10–0.49], respectively). No serious adverse events were reported by study participants. Conclusions The MenACWY conjugate vaccine was less immunogenic in adolescent patients with primary or secondary immunodeficiency compared to healthy controls, urging the need for further surveillance of these patients and supporting considerations for booster MenACWY conjugate vaccinations in these patient groups. |
| first_indexed | 2024-03-12T22:19:05Z |
| format | Article |
| id | doaj.art-b400e167a5fe4753958d4b7c44e6a3b1 |
| institution | Directory Open Access Journal |
| issn | 1546-0096 |
| language | English |
| last_indexed | 2024-03-12T22:19:05Z |
| publishDate | 2023-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Pediatric Rheumatology Online Journal |
| spelling | doaj.art-b400e167a5fe4753958d4b7c44e6a3b12023-07-23T11:09:08ZengBMCPediatric Rheumatology Online Journal1546-00962023-07-012111610.1186/s12969-023-00846-3Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort studyMilou Ohm0Joeri W van Straalen1Gerrie de Joode-Smink2Joris van Montfrans3Marije Bartels4Joanne G van Wildenbeest5Caroline A Lindemans6Roos AW Wennink7Joke H de Boer8Elisabeth AM Sanders9Frans M Verduyn-Lunel10Guy AM Berbers11Nico M Wulffraat12Marc H.A. Jansen13Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM)Department of Pediatric Immunology and Rheumatology, Wilhelmina Children’s Hospital, University Medical Centre UtrechtDepartment of Pediatric Immunology and Rheumatology, Wilhelmina Children’s Hospital, University Medical Centre UtrechtDepartment of Pediatric Immunology and Rheumatology, Wilhelmina Children’s Hospital, University Medical Centre UtrechtDepartment of Pediatric Hematology, Wilhelmina Children’s Hospital, University Medical Centre UtrechtDepartment of Pediatric Infectious Diseases, Wilhelmina Children’s Hospital, University Medical Centre UtrechtDepartment of Pediatric Immunology and Rheumatology, Wilhelmina Children’s Hospital, University Medical Centre UtrechtDepartment of Ophthalmology, University Medical Centre UtrechtDepartment of Ophthalmology, University Medical Centre UtrechtCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM)Department of Medical Microbiology, University Medical Centre UtrechtCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM)Department of Pediatric Immunology and Rheumatology, Wilhelmina Children’s Hospital, University Medical Centre UtrechtDepartment of Pediatric Immunology and Rheumatology, Wilhelmina Children’s Hospital, University Medical Centre UtrechtAbstract Background Immunization with meningococcal ACWY conjugate vaccine induces protective antibodies against invasive meningococcal disease (IMD) caused by serogroups A, C, W and Y. We studied MenACWY-TT vaccine immunogenicity in adolescents with a heterogenous group of primary and secondary immune deficiency including patients with systemic lupus erythematosus, mixed connective tissue disease, vasculitis, uveitis, 22Q11 syndrome, sickle cell disease, and patients who underwent stem cell transplantation for bone marrow failure. Findings We enrolled 69 individuals aged 14–18 years diagnosed with a primary or secondary immune deficiency in a prospective observational cohort study. All patients received a single dose of MenACWY-TT vaccine during the catch-up campaign 2018-19 because of the IMD-W outbreak in the Netherlands. Capsular polysaccharide-specific (PS) IgG concentrations against MenACWY were measured before and 3–6, 12, and 24 months after vaccination. Overall, geometric mean concentrations (GMCs) of MenACWY-PS-specific IgG were lower in patients compared to data from healthy, aged-matched controls (n = 75) reaching significance at 12 months postvaccination for serogroup A and W (adjusted GMC ratios 0.26 [95% CI: 0.15–0.47] and 0.22 [95% CI: 0.10–0.49], respectively). No serious adverse events were reported by study participants. Conclusions The MenACWY conjugate vaccine was less immunogenic in adolescent patients with primary or secondary immunodeficiency compared to healthy controls, urging the need for further surveillance of these patients and supporting considerations for booster MenACWY conjugate vaccinations in these patient groups.https://doi.org/10.1186/s12969-023-00846-3MenACWY conjugate vaccinationAntibody responsesImmunodeficiencyAutoimmune diseaseInflammatory diseaseImmunocompromised |
| spellingShingle | Milou Ohm Joeri W van Straalen Gerrie de Joode-Smink Joris van Montfrans Marije Bartels Joanne G van Wildenbeest Caroline A Lindemans Roos AW Wennink Joke H de Boer Elisabeth AM Sanders Frans M Verduyn-Lunel Guy AM Berbers Nico M Wulffraat Marc H.A. Jansen Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study Pediatric Rheumatology Online Journal MenACWY conjugate vaccination Antibody responses Immunodeficiency Autoimmune disease Inflammatory disease Immunocompromised |
| title | Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study |
| title_full | Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study |
| title_fullStr | Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study |
| title_full_unstemmed | Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study |
| title_short | Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study |
| title_sort | meningococcal acwy conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies a prospective observational cohort study |
| topic | MenACWY conjugate vaccination Antibody responses Immunodeficiency Autoimmune disease Inflammatory disease Immunocompromised |
| url | https://doi.org/10.1186/s12969-023-00846-3 |
| work_keys_str_mv | AT milouohm meningococcalacwyconjugatevaccineimmunogenicityinadolescentswithprimaryorsecondaryimmunedeficienciesaprospectiveobservationalcohortstudy AT joeriwvanstraalen meningococcalacwyconjugatevaccineimmunogenicityinadolescentswithprimaryorsecondaryimmunedeficienciesaprospectiveobservationalcohortstudy AT gerriedejoodesmink meningococcalacwyconjugatevaccineimmunogenicityinadolescentswithprimaryorsecondaryimmunedeficienciesaprospectiveobservationalcohortstudy AT jorisvanmontfrans meningococcalacwyconjugatevaccineimmunogenicityinadolescentswithprimaryorsecondaryimmunedeficienciesaprospectiveobservationalcohortstudy AT marijebartels meningococcalacwyconjugatevaccineimmunogenicityinadolescentswithprimaryorsecondaryimmunedeficienciesaprospectiveobservationalcohortstudy AT joannegvanwildenbeest meningococcalacwyconjugatevaccineimmunogenicityinadolescentswithprimaryorsecondaryimmunedeficienciesaprospectiveobservationalcohortstudy AT carolinealindemans meningococcalacwyconjugatevaccineimmunogenicityinadolescentswithprimaryorsecondaryimmunedeficienciesaprospectiveobservationalcohortstudy AT roosawwennink meningococcalacwyconjugatevaccineimmunogenicityinadolescentswithprimaryorsecondaryimmunedeficienciesaprospectiveobservationalcohortstudy AT jokehdeboer meningococcalacwyconjugatevaccineimmunogenicityinadolescentswithprimaryorsecondaryimmunedeficienciesaprospectiveobservationalcohortstudy AT elisabethamsanders meningococcalacwyconjugatevaccineimmunogenicityinadolescentswithprimaryorsecondaryimmunedeficienciesaprospectiveobservationalcohortstudy AT fransmverduynlunel meningococcalacwyconjugatevaccineimmunogenicityinadolescentswithprimaryorsecondaryimmunedeficienciesaprospectiveobservationalcohortstudy AT guyamberbers meningococcalacwyconjugatevaccineimmunogenicityinadolescentswithprimaryorsecondaryimmunedeficienciesaprospectiveobservationalcohortstudy AT nicomwulffraat meningococcalacwyconjugatevaccineimmunogenicityinadolescentswithprimaryorsecondaryimmunedeficienciesaprospectiveobservationalcohortstudy AT marchajansen meningococcalacwyconjugatevaccineimmunogenicityinadolescentswithprimaryorsecondaryimmunedeficienciesaprospectiveobservationalcohortstudy |